{
  "nodes": [
    {
      "id": "N1",
      "label": "Step 1",
      "customData": {
        "node_id": "A",
        "node_step_index": 0,
        "content": "In September 2016, a 57-year-old man was diagnosed with squamous cell thymic carcinoma (TC) with a diameter of 3.6 cm, involving the sternal manubrium and bone metastases in the sternum and ribs. The stage was IVa according to the Masaoka-Koga system.",
        "clinical_data": {
          "diagnoses": [
            {
              "code": "C37",
              "label": "Malignant neoplasm of thymus",
              "status": "active",
              "onset_date": "2016-09"
            },
            {
              "code": "C79.51",
              "label": "Secondary malignant neoplasm of bone",
              "status": "active",
              "onset_date": "2016-09"
            }
          ],
          "imaging": [
            {
              "type": "imaging",
              "body_part": "sternum",
              "modality": "imaging",
              "finding": "bone metastases",
              "impression": "bone metastases",
              "date": "2016-09"
            },
            {
              "type": "imaging",
              "body_part": "ribs",
              "modality": "imaging",
              "finding": "bone metastases",
              "impression": "bone metastases",
              "date": "2016-09"
            }
          ]
        }
      }
    },
    {
      "id": "N2",
      "label": "Step 2",
      "customData": {
        "node_id": "B",
        "node_step_index": 1,
        "content": "From October 2016 to February 2017, the patient received six courses of first-line chemotherapy with carboplatin and paclitaxel, administered every three weeks.",
        "clinical_data": {
          "medications": [
            {
              "drug": "C0007127",
              "dosage": null,
              "frequency": "every three weeks",
              "modality": "IV",
              "start_date": "2016-10",
              "end_date": "2017-02",
              "indication": null
            },
            {
              "drug": "C0030393",
              "dosage": null,
              "frequency": "every three weeks",
              "modality": "IV",
              "start_date": "2016-10",
              "end_date": "2017-02",
              "indication": null
            }
          ]
        }
      }
    },
    {
      "id": "N3",
      "label": "Step 3",
      "customData": {
        "node_id": "C",
        "node_step_index": 2,
        "content": "After three cycles of chemotherapy, the patient achieved a partial response (PR) according to RECIST 1.1, which was confirmed at the end of the sixth cycle.",
        "clinical_data": {
          "diagnoses": [
            {
              "code": "C0009358",
              "label": "Partial Response",
              "status": "active"
            }
          ]
        }
      }
    },
    {
      "id": "N4",
      "label": "Step 4",
      "customData": {
        "node_id": "D",
        "node_step_index": 3,
        "content": "Sequential radiotherapy was performed on the mediastinal mass, with a dosage of 60 Gy in 30 fractions.",
        "clinical_data": {
          "procedures": [
            {
              "name": "Radiotherapy",
              "approach": "other",
              "date": null,
              "location": "mediastinal mass",
              "performed_by": null,
              "outcome": null
            }
          ]
        }
      }
    },
    {
      "id": "N5",
      "label": "Step 5",
      "customData": {
        "node_id": "E",
        "node_step_index": 4,
        "content": "Four months after the end of the first-line treatment (approximately June 2017), an 18FDG-PET/CT scan showed areas of increased uptake in the 6th and 7th right ribs and progressive disease in the sternal body according to MD Anderson criteria.",
        "clinical_data": {
          "imaging": [
            {
              "type": "18FDG-PET/CT scan",
              "body_part": "ribs",
              "modality": "PET",
              "finding": "increased uptake in the 6th and 7th right ribs",
              "date": "2017-06"
            },
            {
              "type": "18FDG-PET/CT scan",
              "body_part": "sternal body",
              "modality": "PET",
              "finding": "progressive disease",
              "date": "2017-06"
            }
          ]
        }
      }
    },
    {
      "id": "N6",
      "label": "Step 6",
      "customData": {
        "node_id": "F",
        "node_step_index": 5,
        "content": "From July to December 2017, the patient underwent second-line therapy with gemcitabine.",
        "clinical_data": {
          "medications": [
            {
              "drug": "C0017525",
              "dosage": null,
              "frequency": null,
              "modality": null,
              "start_date": "2017-07",
              "end_date": "2017-12",
              "indication": null
            }
          ]
        }
      }
    },
    {
      "id": "N7",
      "label": "Step 7",
      "customData": {
        "node_id": "G",
        "node_step_index": 6,
        "content": "An 18FDG-PET/CT scan revealed progression of the primary mediastinal mass, new lesions in the posterior arch of the 6th right rib and pulmonary hilar lymph node involvement. A CT scan confirmed these findings.",
        "clinical_data": {
          "imaging": [
            {
              "type": "Positron emission tomography/computed tomography",
              "body_part": "mediastinum",
              "modality": "PET",
              "finding": "progression of the primary mediastinal mass",
              "impression": "progression of the primary mediastinal mass"
            },
            {
              "type": "Positron emission tomography/computed tomography",
              "body_part": "rib",
              "modality": "PET",
              "finding": "new lesions in the posterior arch of the 6th right rib",
              "impression": "new lesions in the posterior arch of the 6th right rib"
            },
            {
              "type": "Positron emission tomography/computed tomography",
              "body_part": "pulmonary hilar lymph node",
              "modality": "PET",
              "finding": "pulmonary hilar lymph node involvement",
              "impression": "pulmonary hilar lymph node involvement"
            },
            {
              "type": "Computed tomography",
              "body_part": "mediastinum",
              "modality": "CT",
              "finding": "progression of the primary mediastinal mass",
              "impression": "progression of the primary mediastinal mass"
            },
            {
              "type": "Computed tomography",
              "body_part": "rib",
              "modality": "CT",
              "finding": "new lesions in the posterior arch of the 6th right rib",
              "impression": "new lesions in the posterior arch of the 6th right rib"
            },
            {
              "type": "Computed tomography",
              "body_part": "pulmonary hilar lymph node",
              "modality": "CT",
              "finding": "pulmonary hilar lymph node involvement",
              "impression": "pulmonary hilar lymph node involvement"
            }
          ]
        }
      }
    },
    {
      "id": "N8",
      "label": "Step 8",
      "customData": {
        "node_id": "H",
        "node_step_index": 7,
        "content": "In January 2018, the patient underwent a 68-Gallium (68Ga)-DOTATOC-PET/CT scan, which showed slight somatostatin receptor uptake by both the primary and metastatic lesions.",
        "clinical_data": {
          "imaging": [
            {
              "type": "Positron emission tomography",
              "body_part": "primary and metastatic lesions",
              "modality": "PET",
              "finding": "slight somatostatin receptor uptake",
              "date": "2018-01"
            },
            {
              "type": "Computed tomography",
              "body_part": "primary and metastatic lesions",
              "modality": "CT",
              "finding": "slight somatostatin receptor uptake",
              "date": "2018-01"
            }
          ]
        }
      }
    },
    {
      "id": "N9",
      "label": "Step 9",
      "customData": {
        "node_id": "I",
        "node_step_index": 8,
        "content": "In February 2018, the patient started third-line chemotherapy with a modified ADOC (mADOC) scheme consisting of doxorubicin 40 mg/m2, vincristine 0.60 mg/m2, and cyclophosphamide 700 mg/m2, without cisplatin.",
        "clinical_data": {
          "medications": [
            {
              "drug": "D004324",
              "dosage": "40 mg/m2",
              "frequency": null,
              "modality": null,
              "start_date": "2018-02",
              "end_date": null,
              "indication": null
            },
            {
              "drug": "D014733",
              "dosage": "0.60 mg/m2",
              "frequency": null,
              "modality": null,
              "start_date": "2018-02",
              "end_date": null,
              "indication": null
            },
            {
              "drug": "D003567",
              "dosage": "700 mg/m2",
              "frequency": null,
              "modality": null,
              "start_date": "2018-02",
              "end_date": null,
              "indication": null
            }
          ]
        }
      }
    },
    {
      "id": "N10",
      "label": "Step 10",
      "customData": {
        "node_id": "J",
        "node_step_index": 9,
        "content": "After the third cycle of mADOC, the patient achieved a partial response (PR).",
        "clinical_data": {
          "diagnoses": [
            {
              "code": "C0542358",
              "label": "Partial Response",
              "status": "active"
            }
          ]
        }
      }
    },
    {
      "id": "N11",
      "label": "Step 11",
      "customData": {
        "node_id": "K",
        "node_step_index": 10,
        "content": "Cardiac evaluation before mADOC treatment showed normal heart function with a left ventricular heart fraction (LVHF) of 61%.",
        "clinical_data": {
          "labs": [
            {
              "test": "Left ventricular ejection fraction",
              "value": "61",
              "unit": "%"
            }
          ]
        }
      }
    },
    {
      "id": "N12",
      "label": "Step 12",
      "customData": {
        "node_id": "L",
        "node_step_index": 11,
        "content": "July 2018: Reduction in left ventricular heart fraction (LVHF) to 49% with mild symptoms (class 2 according the New York Heart Association Classification). mADOC treatment was stopped.",
        "timestamp": "2018-07",
        "clinical_data": {
          "diagnoses": [
            {
              "code": "C0238347",
              "label": "Left Ventricular Dysfunction",
              "status": "active",
              "onset_date": "2018-07"
            }
          ],
          "functional_status": [
            {
              "domain": "cardiovascular",
              "description": "mild symptoms (class 2 according the New York Heart Association Classification)",
              "score": "2",
              "scale": "New York Heart Association Classification"
            }
          ]
        }
      }
    },
    {
      "id": "N13",
      "label": "Step 13",
      "customData": {
        "node_id": "M",
        "node_step_index": 12,
        "content": "Echocardiography showed concentric left ventricular hypertrophy and cardiac hypokinesia, with a further decrease in LVHF to 43%.",
        "clinical_data": {
          "imaging": [
            {
              "type": "Echocardiography",
              "body_part": "Heart",
              "modality": "Ultrasound",
              "finding": "concentric left ventricular hypertrophy and cardiac hypokinesia",
              "impression": "further decrease in LVHF to 43%"
            }
          ]
        }
      }
    }
  ],
  "edges": [
    {
      "from": "N1",
      "to": "N2",
      "data": {
        "edge_id": "A_to_B",
        "branch_flag": true,
        "content": "Initiation of first-line chemotherapy.",
        "transition_event": {
          "trigger_type": "medication_change",
          "trigger_entities": [
            "C0007127",
            "C0030393"
          ],
          "change_type": "addition",
          "target_domain": "medication",
          "timestamp": "2016-10"
        }
      }
    },
    {
      "from": "N2",
      "to": "N3",
      "data": {
        "edge_id": "B_to_C",
        "branch_flag": true,
        "content": "Response to chemotherapy.",
        "transition_event": {
          "trigger_type": "interpretation",
          "trigger_entities": [
            "C0009358"
          ],
          "change_type": "other",
          "target_domain": "diagnosis"
        }
      }
    },
    {
      "from": "N3",
      "to": "N4",
      "data": {
        "edge_id": "C_to_D",
        "branch_flag": true,
        "content": "Initiation of radiotherapy.",
        "transition_event": {
          "trigger_type": "procedure",
          "trigger_entities": [],
          "change_type": "addition",
          "target_domain": "procedure"
        }
      }
    },
    {
      "from": "N4",
      "to": "N5",
      "data": {
        "edge_id": "D_to_E",
        "branch_flag": true,
        "content": "Disease progression after first-line treatment.",
        "transition_event": {
          "trigger_type": "imaging",
          "trigger_entities": [],
          "change_type": "progression",
          "target_domain": "imaging",
          "timestamp": "2017-06"
        }
      }
    },
    {
      "from": "N5",
      "to": "N6",
      "data": {
        "edge_id": "E_to_F",
        "branch_flag": true,
        "content": "Initiation of second-line chemotherapy with gemcitabine.",
        "transition_event": {
          "trigger_type": "medication_change",
          "trigger_entities": [
            "C0017525"
          ],
          "change_type": "addition",
          "target_domain": "medication",
          "timestamp": "2017-07"
        }
      }
    },
    {
      "from": "N6",
      "to": "N7",
      "data": {
        "edge_id": "F_to_G",
        "branch_flag": true,
        "content": "Disease progression during second-line chemotherapy.",
        "transition_event": {
          "trigger_type": "imaging",
          "trigger_entities": [],
          "change_type": "progression",
          "target_domain": "imaging"
        }
      }
    },
    {
      "from": "N7",
      "to": "N8",
      "data": {
        "edge_id": "G_to_H",
        "branch_flag": true,
        "content": "68Ga-DOTATOC-PET/CT scan showing somatostatin receptor uptake.",
        "transition_event": {
          "trigger_type": "imaging",
          "trigger_entities": [],
          "change_type": "other",
          "target_domain": "imaging",
          "timestamp": "2018-01"
        }
      }
    },
    {
      "from": "N8",
      "to": "N9",
      "data": {
        "edge_id": "H_to_I",
        "branch_flag": true,
        "content": "Initiation of third-line chemotherapy with mADOC.",
        "transition_event": {
          "trigger_type": "medication_change",
          "trigger_entities": [
            "D004324",
            "D014733",
            "D003567"
          ],
          "change_type": "addition",
          "target_domain": "medication",
          "timestamp": "2018-02"
        }
      }
    },
    {
      "from": "N9",
      "to": "N10",
      "data": {
        "edge_id": "I_to_J",
        "branch_flag": true,
        "content": "Partial response to mADOC chemotherapy.",
        "transition_event": {
          "trigger_type": "interpretation"
        }
      }
    }
  ]
}